Trial
NCT06903286
Extension Study of Participants From SPG302-ALS-001
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Spinogenix
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis (ALS)
Intervention
SPG302
Why stopped
patients treated through compassionate use program
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-17